ClinicalTrials.gg
CompletedNCT07847242Updated Oct 7, 2026

Brain Connectivity and Inflammatory Markers During Short-Term Psychotherapy for Treatment-Resistant Depression

An interventional study of Short-Term Dynamic Psychotherapy and Mindfulness-Based Cognitive Therapy in Depressive Disorder, Treatment-Resistant, sponsored by Korea University Ansan Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Korea University Ansan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 7 months after the study started (first participant enrolled Feb 2022, registered Sep 2026).
Updated Oct 2, 2026Eligibility revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

Some adults continue to experience depression despite treatment with antidepressant medicines. This study aimed to explore relationships between depression symptoms, brain function, and blood markers of inflammation, and changes in these measures during a course of psychotherapy.

Adults with treatment-resistant depression were assigned to receive 10 weekly sessions of individual short-term dynamic psychotherapy, a form of talking therapy, alongside their ongoing medication. Healthy adults served as a reference group and received no study treatment.

Assessments were planned at the start of participation and at a 10-week follow-up. These included depression ratings, quality-of-life questionnaires, blood tests, and measurements of brain activity. The study aimed to compare initial measurements between participants with depression and healthy adults and to explore changes over time within each group.

Read the detailed description

This was a single-center, prospective, nonrandomized interventional pilot study conducted at the Department of Psychiatry, Korea University Ansan Hospital, Republic of Korea.

The protocol initially planned a mindfulness-based cognitive therapy (MBCT) group, an individual psychotherapy group, and a healthy reference group. A protocol amendment removed the planned random allocation between the two psychotherapy groups because irregular recruitment could delay treatment while waiting to form MBCT groups. In the study as conducted, all enrolled participants with treatment-resistant depression were assigned to individual short-term dynamic psychotherapy alongside ongoing pharmacotherapy. No participants received MBCT. Healthy participants served as a reference group for clinical and biological measurements.

The broader protocol included clinical assessments, peripheral inflammatory and neurotrophic markers, and measures of brain function. Functional near-infrared spectroscopy (fNIRS) was specified to examine prefrontal cortical activity and connectivity. Functional magnetic resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS) were used to examine resting-state brain networks and neurochemical measures. Additional planned procedures included stool collection for exploratory gut microbiome analyses and storage of peripheral blood mononuclear cells for laboratory research involving induced pluripotent stem cells.

02

Conditions studied

  • Depressive Disorder, Treatment-Resistant

Keywords

  • Short-Term Dynamic Psychotherapy
  • Psychodynamic Psychotherapy
  • Inflammatory Biomarkers
  • Functional Near-Infrared Spectroscopy
  • Functional Connectivity
  • Quality of Life
03

In context

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

This study's enrollment of 31 is below the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.

Browse Depressive Disorder, Treatment-Resistant studies →

Lead sponsor

Korea University Ansan Hospital is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

  • Aged 19 to 65 years.
  • All four grandparents are Korean.
  • Able to understand the study information and provide voluntary .

Participants with treatment-resistant depression:

  • Persistent depressive symptoms despite treatment with at least two antidepressants for at least 6 weeks.
  • A 17-item Hamilton Depression Rating Scale (HAM-D) score of 17 or higher.
  • A history of at least two major depressive episodes.
  • First major depressive episode at age 14 years or older and before age 50 years.

Healthy participants:

- No current or past psychiatric disorder.

Exclusion criteria

Exclusion Criteria:

  • History of bipolar disorder or psychosis.
  • History of alcohol or other substance dependence predating the onset of depression.
  • History of intellectual disability.
  • A parent or grandparent who is not Korean.
  • History of significant central nervous system disease, including traumatic brain injury, loss of consciousness, Parkinson's disease, epilepsy, Alzheimer's disease, or Huntington's disease.
  • Current infection, infection within the preceding 3 months, or an state. Immunocompromised states include congenital immune impairment and acquired conditions associated with immunosuppressive treatment, previous or current chemotherapy, or (HIV) infection.
  • Ongoing long-term use of oral or nonsteroidal anti-inflammatory drugs.
  • Pregnancy or breastfeeding.
  • suicide risk in the judgment of the treating psychiatrist or investigator.
  • Thoughts or intent to harm others.
  • Use of an unapproved drug within the preceding 30 days or current participation in a related clinical study.
  • Clinically significant abnormal screening findings in the judgment of the principal investigator.
  • An acute or chronic illness that makes participation unsuitable in the investigator's judgment.
  • Likely inability to follow study procedures and requirements.
  • Coronavirus disease 2019 (COVID-19) vaccination within the preceding month.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Short-Term Dynamic Psychotherapy

    Fifteen participants with treatment-resistant depression were assigned to receive 10 weekly sessions of individual short-term dynamic psychotherapy alongside ongoing pharmacotherapy. Assessments were scheduled at baseline and week 10.

    Behavioral: Short-Term Dynamic Psychotherapy

  • No intervention
    Healthy Reference Group

    Sixteen healthy participants were enrolled as a reference group. They received no study treatment. Clinical and biological assessments were scheduled at baseline and week 10.

  • Experimental
    Mindfulness-Based Cognitive Therapy (Not Implemented)

    This arm was specified in the approved protocol to receive a 10-week course of group mindfulness-based cognitive therapy. The arm was not implemented. No participants were enrolled, and the intervention was not delivered.

    Behavioral: Mindfulness-Based Cognitive Therapy

Interventions

  • BehavioralShort-Term Dynamic Psychotherapy

    Individual short-term dynamic psychotherapy was provided once weekly over a planned 10-week course, in addition to ongoing pharmacotherapy.

    Also known as: STDP

  • BehavioralMindfulness-Based Cognitive Therapy

    The protocol planned group mindfulness-based cognitive therapy comprising 10 weekly 50-minute sessions, to be delivered via Zoom or in person at the hospital. This intervention was not implemented, and no participants received it.

    Also known as: MBCT

06

What researchers measure

Primary outcomes

  1. Change from Baseline in 17-Item Hamilton Depression Rating Scale (HAM-D) Total Score

    Depressive symptom severity was assessed by the treating psychiatrist using the Korean version of the 17-item Hamilton Depression Rating Scale (K-HDRS). Total scores range from 0 to 52, with higher scores indicating more severe depressive symptoms. Change in total score was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  2. Change from Baseline in Mean Prefrontal Functional Connectivity (fNIRS)

    Resting-state functional connectivity was assessed from 5-minute recordings using a 48-channel prefrontal fNIRS system (NIRSIT). Pairwise Pearson correlations were calculated from preprocessed oxygenated hemoglobin time series, transformed using Fisher's r-to-z transformation, and summarized as mean connectivity across the recorded prefrontal network. Connectivity values are dimensionless. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  3. Change from Baseline in the Area Under the Small-Worldness Curve Across Correlation Thresholds (fNIRS)

    Small-worldness of the prefrontal functional network was calculated from resting-state fNIRS oxygenated hemoglobin signals. Binary networks were constructed using Pearson correlation thresholds of 0.2, 0.3, 0.4, 0.5, and 0.6. Small-worldness was summarized as the area under the curve across these thresholds using trapezoidal integration. This measure is dimensionless. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  4. Change from Baseline in the Area Under the Mean Clustering Coefficient Curve Across Correlation Thresholds (fNIRS)

    Mean clustering coefficient of the prefrontal functional network was calculated from resting-state fNIRS oxygenated hemoglobin signals. Binary networks were constructed using Pearson correlation thresholds of 0.2, 0.3, 0.4, 0.5, and 0.6. Mean clustering coefficient was summarized as the area under the curve across these thresholds using trapezoidal integration. This measure is dimensionless. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  5. Change from Baseline in the Area Under the Local Efficiency Curve Across Correlation Thresholds (fNIRS)

    Local efficiency of the prefrontal functional network was calculated from resting-state fNIRS oxygenated hemoglobin signals. Binary networks were constructed using Pearson correlation thresholds of 0.2, 0.3, 0.4, 0.5, and 0.6. Local efficiency was summarized as the area under the curve across these thresholds using trapezoidal integration. This measure is dimensionless. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  6. Change from Baseline in the Area Under the Global Efficiency Curve Across Correlation Thresholds (fNIRS)

    Global efficiency of the prefrontal functional network was calculated from resting-state fNIRS oxygenated hemoglobin signals. Binary networks were constructed using Pearson correlation thresholds of 0.2, 0.3, 0.4, 0.5, and 0.6. Global efficiency was summarized as the area under the curve across these thresholds using trapezoidal integration. This measure is dimensionless. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  7. Change from Baseline in Resting-State Brain Functional Connectivity Assessed by fMRI

    Resting-state functional magnetic resonance imaging (fMRI) was used to assess brain functional connectivity. The outcome is change in functional connectivity from baseline to week 10.

    Time frame: Baseline and week 10

  8. Brain Metabolite Concentrations Measured by Magnetic Resonance Spectroscopy (MRS)

    Brain metabolite concentrations were assessed using magnetic resonance spectroscopy (MRS). The protocol specified measurements at baseline and week 10.

    Time frame: Baseline and week 10

Secondary outcomes

  1. Change from Baseline in the Sum of the Four World Health Organization Quality of Life Assessment Instrument-Brief Form (WHOQOL-BREF) Domain Scores

    Quality of life was assessed using the Korean version of the WHOQOL-BREF. A study-defined summary score was calculated by summing the four domain scores, each expressed on a 4-20 scale. The two general items (Q1 and Q2) were excluded. Summary scores range from 16 to 80, with higher scores indicating better quality of life. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  2. Change from Baseline in Serum Interleukin-6 (IL-6) Concentration

    Serum interleukin-6 (IL-6) was measured using a magnetic bead-based multiplex immunoassay on a Luminex 200 platform. Assay-reported values were expressed in pg/mL. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  3. Change from Baseline in Serum Tumor Necrosis Factor-Alpha (TNF-alpha) Concentration

    Serum tumor necrosis factor-alpha (TNF-alpha) was measured using a magnetic bead-based multiplex immunoassay on a Luminex 200 platform. Assay-reported values were expressed in pg/mL. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  4. Change from Baseline in C-Reactive Protein (CRP) Concentration

    C-reactive protein (CRP) was measured in the hospital clinical laboratory using automated immunoturbidimetry. Values were expressed in mg/L. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  5. Change from Baseline in Serum Brain-Derived Neurotrophic Factor (BDNF) Concentration

    Serum brain-derived neurotrophic factor (BDNF) was measured using a magnetic bead-based multiplex immunoassay on a Luminex 200 platform. Values were expressed in pg/mL. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  6. Change from Baseline in Serum Interleukin-1 Beta (IL-1beta) Concentration

    Serum interleukin-1 beta (IL-1beta) was measured using a magnetic bead-based multiplex immunoassay on a Luminex 200 platform. Assay-reported values were expressed in pg/mL. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  7. Change from Baseline in Serum Interleukin-10 (IL-10) Concentration

    Serum interleukin-10 (IL-10) was measured using a magnetic bead-based multiplex immunoassay on a Luminex 200 platform. Assay-reported values were expressed in pg/mL. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  8. Change from Baseline in Erythrocyte Sedimentation Rate (ESR)

    Erythrocyte sedimentation rate (ESR) was measured in anticoagulated whole blood using the hospital laboratory's routine automated method. Values were expressed in mm/h. Change was assessed between baseline and week 10.

    Time frame: Baseline and week 10

  9. Five Facet Mindfulness Questionnaire (FFMQ) Mean Item Score

    Mindfulness was assessed using the 39-item Korean version of the Five Facet Mindfulness Questionnaire (FFMQ). The questionnaire covers observing, describing, acting with awareness, nonjudging of inner experience, and nonreactivity to inner experience. Items are rated from 1 to 5. The overall score was recorded as a mean item score on a 1-5 scale, with higher scores indicating greater mindfulness. Assessments were recorded at baseline and week 10.

    Time frame: Baseline and week 10

  10. Relative Abundance of Gut Microbial Taxa

    Gut microbiota composition was assessed by 16S ribosomal ribonucleic acid (rRNA) gene amplicon analysis of stool samples targeting the V3-V4 region. Relative abundances of microbial taxa were calculated at taxonomic levels from phylum to species and expressed as proportions ranging from 0 to 1. Assessments were recorded at baseline and week 10.

    Time frame: Baseline and week 10

07

Study locations

1 site
  • Korea University Ansan Hospital
    Ansan, Gyeonggi-do 15355, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the findings reported in publications arising from this clinical trial may be made available upon reasonable request, subject to institutional and ethical approval.

Time frame: Data underlying each publication arising from this clinical trial may be made available after that publication and for as long as the data are retained in accordance with applicable institutional and ethical requirements.

Access criteria: Researchers may request access by contacting the principal investigator, Sangho Shin, at sangho_shin@kyuh.ac.kr. Requests should specify the data sought and the intended research use. Data access is subject to institutional and ethical approval.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2023, 18 months.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's 18 months is below that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartActual
Feb 15, 2022
Primary completionActual
Aug 26, 2023
CompletionActual
Aug 26, 2023
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedCurrent infection, infection within the preceding 3 months, or an immunocompromised state. Immunocompromised states include congenital immune impairment and acquired conditions associated with immunosuppressive treatment, previous or current chemotherapy, or human immunodeficiency virus (HIV) infection.
  • EditedCoronavirus disease 2019 (COVID-19) vaccination within the preceding month.
Oct 2, 2026
Secondary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedChange from Baseline in the Sum of the Four World Health Organization Quality of Life Assessment Instrument-Brief Form (WHOQOL-BREF) Domain ScoresTime frame: Baseline and week 10
  • DescriptionRelative Abundance of Gut Microbial Taxa: how it is measured was reworded
Oct 2, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 3 updates
  1. Oct 7, 2026
    Minor edits only
    + 2 other changes: verification date and data sharing statement
  2. Oct 2, 2026
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedCurrent infection, infection within the preceding 3 months, or an immunocompromised state. Immunocompromised states include congenital immune impairment and acquired conditions associated with immunosuppressive treatment, previous or current chemotherapy, or human immunodeficiency virus (HIV) infection.
    • EditedCoronavirus disease 2019 (COVID-19) vaccination within the preceding month.
    Secondary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedChange from Baseline in the Sum of the Four World Health Organization Quality of Life Assessment Instrument-Brief Form (WHOQOL-BREF) Domain ScoresTime frame: Baseline and week 10
    • DescriptionRelative Abundance of Gut Microbial Taxa: how it is measured was reworded
    + 1 other change: description
  3. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847242
Lead sponsor
Korea University Ansan Hospital
Collaborators
National Research Foundation of Korea, Konyang University Hospital
Responsible party
Shin, Sangho (Associate Professor, Konyang University Hospital) — Principal investigator
First posted
Sep 29, 2026
Start date
Feb 15, 2022
Primary completion
Aug 26, 2023
Completion
Aug 26, 2023
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion